サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1720839

神経線維腫症1型の世界市場レポート 2025年

Neurofibromatosis Type 1 Global Market Report 2025

出版日
ページ情報
英文 175 Pages
納期
2～10営業日
カスタマイズ可能
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
神経線維腫症1型の世界市場レポート 2025年
出版日: 2025年05月01日
発行: The Business Research Company
ページ情報: 英文 175 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

神経線維腫症1型（NF1）の市場規模は、今後数年間で力強い成長が見込まれます。2029年にはCAGR9.6％で127億7,000万米ドルに成長します。予測期間中の成長は、血液がん症例の増加、叢状腫瘍の発生率の増加、神経鞘腫瘍の有病率の増加、神経線維腫症の発生率の増加、神経線維腫症治療の使用拡大などに起因しています。この期間の主な動向には、進行中の研究開発、新しい治療法の創出、診断技術の進歩、腫瘍特異的治療、新薬の開発などが含まれます。

自然（de novo）突然変異の増加が神経線維腫症1型（NF1）市場の成長を牽引すると予想されます。自然（de novo）変異とは、親からの遺伝ではなく、DNA複製時のエラーや環境の影響により、個体で初めて発生する遺伝的変化を指します。このような突然変異の発生が増加している背景には、親の高齢化、放射線や化学物質などの環境暴露、細胞分裂時のDNA複製エラーなどの要因が関係しています。神経線維腫症1型（NF1）は特にde novo変異を起こしやすく、NF1遺伝子は配偶子形成期に大きな欠失、挿入、点突然変異を含む高い変異率を経験します。そのため、家族歴のないNF1患者が新たに発生します。例えば、2023年8月に『Molecular Biology and Evolution』誌が発表した報告では、特定の家系に534の潜在的なde novo変異（DNM）が見つかっています。したがって、自然（de novo）突然変異がNF1市場の成長に寄与しています。

NF1市場の企業は、標的治療と患者の転帰を改善するために、キナーゼ阻害剤などの革新的な治療を導入しています。キナーゼ阻害剤は、リン酸基をタンパク質に転移させ、様々な細胞プロセスを制御する酵素であるキナーゼの活性を阻害する薬剤です。2023年5月、英国の製薬会社アストラゼネカは、3歳以上のNF1小児患者における症候性で手術不能な叢状神経線維腫（PN）の治療薬として、キナーゼ阻害薬であるKoselugo（selumetinib）の承認を中国で取得しました。今回の承認により、小児NF1患者に対する標的治療の選択肢が広がり、疾患管理とQOLが改善されます。コセルゴ（一般名：セルメチニブ）の中国での導入は、精密医療が重視されるようになり、手術不能な叢状神経線維腫を管理するための非手術的選択肢を提供するものです。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

  • 世界神経線維腫症1型PESTEL分析（政治、社会、技術、環境、法的要因、促進要因と抑制要因）
  • 最終用途産業の分析
  • 世界の神経線維腫症1型市場：成長率分析
  • 世界の神経線維腫症1型市場の実績：規模と成長, 2019-2024
  • 世界の神経線維腫症1型市場の予測：規模と成長, 2024-2029, 2034F
  • 世界神経線維腫症1型総アドレス可能市場（TAM）

第6章 市場セグメンテーション

  • 世界の神経線維腫症1型市場治療別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 薬
  • 手術
  • 放射線治療
  • その他の治療法
  • 世界の神経線維腫症1型市場：疾患タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 叢状神経線維腫
  • 皮膚神経線維腫
  • 視神経膠腫
  • その他の病気
  • 世界の神経線維腫症1型市場：流通チャネル別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院薬局
  • 小売薬局
  • オンライン薬局
  • 世界の神経線維腫症1型市場：エンドユーザー別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 病院
  • 専門クリニック
  • 外来手術センター
  • その他のエンドユーザー
  • 世界の神経線維腫症1型市場、医薬品の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 標的療法
  • 疼痛管理薬
  • 抗けいれん薬
  • 世界の神経線維腫症1型市場、手術の種類別の細分化、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 腫瘍除去手術
  • 神経減圧手術
  • 世界の神経線維腫症1型市場放射線治療の種類別サブセグメンテーション、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 定位放射線手術
  • 外部放射線療法
  • 世界の神経線維腫症1型市場、その他の治療法のサブセグメンテーション、タイプ別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 理学療法
  • 遺伝カウンセリング
  • 心理的サポートとカウンセリング

第7章 地域別・国別分析

  • 世界の神経線維腫症1型市場：地域別、実績と予測, 2019-2024, 2024-2029F, 2034F
  • 世界の神経線維腫症1型市場：国別、実績と予測, 2019-2024, 2024-2029F, 2034F

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

  • 神経線維腫症1型市場：競合情勢
  • 神経線維腫症1型市場：企業プロファイル
    • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
    • Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

  • Takeda Pharmaceutical Company Limited
  • Boehringer Ingelheim International GmbH
  • Vertex Pharmaceuticals Incorporated
  • Shanghai Fosun Pharmaceutical（Group）Co. Ltd
  • BeiGene Ltd.
  • BioMarin Pharmaceutical Inc
  • Exelixis Inc.
  • Blueprint Medicines Corporation
  • SpringWorks Therapeutics Inc
  • Onclive LLC
  • Healx Limited
  • Infixion Bioscience Limited
  • NFlection Therapeutics Inc
  • Pasithea Therapeutics Corporation
  • Mulberry Biotherapeutics Inc.

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

  • 神経線維腫症1型市場2029：新たな機会を提供する国
  • 神経線維腫症1型市場2029：新たな機会を提供するセグメント
  • 神経線維腫症1型市場2029：成長戦略
    • 市場動向に基づく戦略
    • 競合の戦略

第36章 付録

目次
Product Code: r34096

Neurofibromatosis type 1 (NF1) is a genetic disorder that primarily impacts the nervous system, leading to the formation of benign tumors along nerves in areas such as the skin, brain, and other parts of the body. It is caused by mutations in the NF1 gene, which results in a deficiency of neurofibromin, a protein responsible for regulating cell growth. This deficiency causes a range of symptoms, including cafe-au-lait spots (light brown patches on the skin), freckling in uncommon areas, learning difficulties, skeletal issues, and, in some instances, vision or nerve-related problems.

The primary treatment for neurofibromatosis type 1 (NF1) generally involves medication, surgery, radiation therapy, and other forms of treatment. Medications used in NF1 include pharmaceutical options such as MEK inhibitors, pain relievers, and antihypertensive drugs, which help to slow tumor growth, alleviate pain, and manage associated complications. The disease encompasses conditions such as plexiform neurofibromas, cutaneous neurofibromas, optic gliomas, and others. These treatments are distributed through various channels, including hospital pharmacies, retail pharmacies, and online pharmacies, and are used by different healthcare providers, including hospitals, specialty clinics, ambulatory surgical centers, and other medical facilities.

The neurofibromatosis type 1 (NF1) market research report is one of a series of new reports from The Business Research Company that provides neurofibromatosis type 1 (NF1) market statistics, including the neurofibromatosis type 1 (NF1) industry global market size, regional shares, competitors with the neurofibromatosis type 1 (NF1) market share, detailed neurofibromatosis type 1 (NF1) market segments, market trends, and opportunities, and any further data you may need to thrive in the neurofibromatosis type 1 (NF1) industry. This neurofibromatosis type 1 (NF1) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The neurofibromatosis type 1 (NF1) market size has grown strongly in recent years. It will grow from $8.06 billion in 2024 to $8.86 billion in 2025 at a compound annual growth rate (CAGR) of 9.9%. The growth during the historical period can be credited to factors such as increased awareness, higher healthcare spending, population growth, supportive government policies, and advancements in medical infrastructure.

The neurofibromatosis type 1 (NF1) market size is expected to see strong growth in the next few years. It will grow to $12.77 billion in 2029 at a compound annual growth rate (CAGR) of 9.6%. The growth during the forecast period can be attributed to the rising number of blood cancer cases, an increase in the incidence of plexiform tumors, a higher prevalence of nerve sheath tumors, the growing occurrence of neurofibromatosis, and the expanding use of neurofibromatosis treatments. Key trends during this period include ongoing research and development, the creation of new therapies, advancements in diagnostic techniques, tumor-specific treatments, and the development of new medications.

The rise in spontaneous (de novo) mutations is expected to drive the growth of the neurofibromatosis type 1 (NF1) market. A spontaneous (de novo) mutation refers to a genetic change that occurs for the first time in an individual, due to errors during DNA replication or environmental influences, rather than being inherited from parents. The increasing occurrence of these mutations is linked to factors such as advanced parental age, environmental exposures such as radiation and chemicals, and errors in DNA replication during cell division. Neurofibromatosis type 1 (NF1) is particularly prone to de novo mutations, as the NF1 gene experiences a high mutation rate, including large deletions, insertions, or point mutations during gametogenesis. This leads to new cases of NF1 without a family history. For example, a report published in August 2023 by the journal Molecular Biology and Evolution found 534 potential de novo mutations (DNMs) in certain families. Therefore, spontaneous (de novo) mutations are contributing to the growth of the NF1 market.

Companies in the NF1 market are introducing innovative treatments, such as kinase inhibitors, to improve targeted therapy and patient outcomes. Kinase inhibitors are drugs that block the activity of kinases, enzymes responsible for transferring phosphate groups to proteins and regulating various cellular processes. In May 2023, AstraZeneca plc, a UK-based pharmaceutical company, received approval in China for Koselugo (selumetinib), a kinase inhibitor, to treat symptomatic, inoperable plexiform neurofibromas (PN) in pediatric patients with NF1, aged three years and older. This approval expands targeted treatment options for pediatric NF1 patients, improving disease management and quality of life. The introduction of Koselugo (selumetinib) in China is in line with the growing emphasis on precision medicine, providing a non-surgical option for managing inoperable plexiform neurofibromas.

In October 2022, Pasithea Therapeutics Corp., a US-based biotechnology company, acquired AlloMek Therapeutics LLC for an undisclosed amount. This acquisition aims to advance Pasithea Therapeutics' efforts in developing treatments for central nervous system disorders and other conditions, as well as establishing anti-depression clinics and offering business support services. AlloMek Therapeutics LLC is involved in developing therapeutics for catastrophic cardiomyopathy, congenital muscular diseases, and neurofibromatosis type 1, contributing to the expansion of NF1 treatment options.

Major players in the neurofibromatosis type 1 (NF1) market are Pfizer Inc., F. Hoffmann-La Roche Ltd, Merck & Co. Inc, Novartis AG, AstraZeneca Plc, Takeda Pharmaceutical Company Limited, Boehringer Ingelheim International GmbH, Vertex Pharmaceuticals Incorporated, Shanghai Fosun Pharmaceutical (Group) Co. Ltd, BeiGene Ltd., BioMarin Pharmaceutical Inc, Exelixis Inc., Blueprint Medicines Corporation, SpringWorks Therapeutics Inc, Onclive LLC, Healx Limited, Infixion Bioscience Limited, NFlection Therapeutics Inc, Pasithea Therapeutics Corporation, Mulberry Biotherapeutics Inc.

North America was the largest region in the neurofibromatosis type 1 (NF1) market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in neurofibromatosis type 1 (NF1) report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the neurofibromatosis type 1 (NF1) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The neurofibromatosis type 1 (NF1) market consists of revenues earned by entities by providing services such as medical monitoring, genetic counselling, and specialized care. The market value includes the value of related goods sold by the service provider or included within the service offering. The neurofibromatosis type 1 (NF1) market also includes sales of medical devices, MEK inhibitors, anticonvulsants, and analgesics. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Neurofibromatosis Type 1 Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on neurofibromatosis type 1 market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

  • Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
  • Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
  • Create regional and country strategies on the basis of local data and analysis.
  • Identify growth segments for investment.
  • Outperform competitors using forecast data and the drivers and trends shaping the market.
  • Understand customers based on the latest market shares.
  • Benchmark performance against key competitors.
  • Suitable for supporting your internal and external presentations with reliable high quality data and analysis
  • Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
  • All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for neurofibromatosis type 1 ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The neurofibromatosis type 1 market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

  • The market characteristics section of the report defines and explains the market.
  • The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
  • The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

  • Market segmentations break down the market into sub markets.
  • The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
  • The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
  • The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

  • Markets Covered:1) By Treatment: Medication; Surgery; Radiation Therapy; Other Treatments
  • 2) By Disease Type: Plexiform Neurofibromas; Cutaneous Neurofibromas; Optic Gliomas; Other Diseases
  • 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Online Pharmacies
  • 4) By End Users: Hospitals; Speciality Clinics; Ambulatory Surgical Centers; Other End Users
  • Subsegments:
  • 1) By Medication: Targeted Therapy; Pain Management Medications; Anticonvulsants
  • 2) By Surgery: Tumor Removal Surgery; Nerve Decompression Surgery
  • 3) By Radiation Therapy: Stereotactic Radiosurgery; External Beam Radiation Therapy
  • 4) By Other Treatments: Physical Therapy; Genetic Counseling; Psychological Support And Counseling
  • Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd; Merck & Co. Inc; Novartis AG; AstraZeneca Plc
  • Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
  • Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
  • Time series: Five years historic and ten years forecast.
  • Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
  • Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
  • Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
  • Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Neurofibromatosis Type 1 Market Characteristics

3. Neurofibromatosis Type 1 Market Trends And Strategies

4. Neurofibromatosis Type 1 Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Neurofibromatosis Type 1 Growth Analysis And Strategic Analysis Framework

  • 5.1. Global Neurofibromatosis Type 1 PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
  • 5.2. Analysis Of End Use Industries
  • 5.3. Global Neurofibromatosis Type 1 Market Growth Rate Analysis
  • 5.4. Global Neurofibromatosis Type 1 Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
  • 5.5. Global Neurofibromatosis Type 1 Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
  • 5.6. Global Neurofibromatosis Type 1 Total Addressable Market (TAM)

6. Neurofibromatosis Type 1 Market Segmentation

  • 6.1. Global Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Medication
  • Surgery
  • Radiation Therapy
  • Other Treatments
  • 6.2. Global Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Plexiform Neurofibromas
  • Cutaneous Neurofibromas
  • Optic Gliomas
  • Other Diseases
  • 6.3. Global Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • 6.4. Global Neurofibromatosis Type 1 Market, Segmentation By End Users, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Hospitals
  • Speciality Clinics
  • Ambulatory Surgical Centers
  • Other End Users
  • 6.5. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Medication, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Targeted Therapy
  • Pain Management Medications
  • Anticonvulsants
  • 6.6. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Surgery, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Tumor Removal Surgery
  • Nerve Decompression Surgery
  • 6.7. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Radiation Therapy, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Stereotactic Radiosurgery
  • External Beam Radiation Therapy
  • 6.8. Global Neurofibromatosis Type 1 Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • Physical Therapy
  • Genetic Counseling
  • Psychological Support And Counseling

7. Neurofibromatosis Type 1 Market Regional And Country Analysis

  • 7.1. Global Neurofibromatosis Type 1 Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 7.2. Global Neurofibromatosis Type 1 Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Neurofibromatosis Type 1 Market

  • 8.1. Asia-Pacific Neurofibromatosis Type 1 Market Overview
  • Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
  • 8.2. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.3. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 8.4. Asia-Pacific Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Neurofibromatosis Type 1 Market

  • 9.1. China Neurofibromatosis Type 1 Market Overview
  • 9.2. China Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.3. China Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
  • 9.4. China Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Neurofibromatosis Type 1 Market

  • 10.1. India Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.2. India Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 10.3. India Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Neurofibromatosis Type 1 Market

  • 11.1. Japan Neurofibromatosis Type 1 Market Overview
  • 11.2. Japan Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.3. Japan Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 11.4. Japan Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Neurofibromatosis Type 1 Market

  • 12.1. Australia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.2. Australia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 12.3. Australia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Neurofibromatosis Type 1 Market

  • 13.1. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.2. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 13.3. Indonesia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Neurofibromatosis Type 1 Market

  • 14.1. South Korea Neurofibromatosis Type 1 Market Overview
  • 14.2. South Korea Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.3. South Korea Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 14.4. South Korea Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Neurofibromatosis Type 1 Market

  • 15.1. Western Europe Neurofibromatosis Type 1 Market Overview
  • 15.2. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.3. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 15.4. Western Europe Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Neurofibromatosis Type 1 Market

  • 16.1. UK Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.2. UK Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 16.3. UK Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Neurofibromatosis Type 1 Market

  • 17.1. Germany Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.2. Germany Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 17.3. Germany Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Neurofibromatosis Type 1 Market

  • 18.1. France Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.2. France Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 18.3. France Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Neurofibromatosis Type 1 Market

  • 19.1. Italy Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.2. Italy Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 19.3. Italy Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Neurofibromatosis Type 1 Market

  • 20.1. Spain Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.2. Spain Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 20.3. Spain Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Neurofibromatosis Type 1 Market

  • 21.1. Eastern Europe Neurofibromatosis Type 1 Market Overview
  • 21.2. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.3. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 21.4. Eastern Europe Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Neurofibromatosis Type 1 Market

  • 22.1. Russia Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.2. Russia Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 22.3. Russia Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Neurofibromatosis Type 1 Market

  • 23.1. North America Neurofibromatosis Type 1 Market Overview
  • 23.2. North America Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.3. North America Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 23.4. North America Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Neurofibromatosis Type 1 Market

  • 24.1. USA Neurofibromatosis Type 1 Market Overview
  • 24.2. USA Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.3. USA Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 24.4. USA Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Neurofibromatosis Type 1 Market

  • 25.1. Canada Neurofibromatosis Type 1 Market Overview
  • 25.2. Canada Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.3. Canada Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 25.4. Canada Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Neurofibromatosis Type 1 Market

  • 26.1. South America Neurofibromatosis Type 1 Market Overview
  • 26.2. South America Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.3. South America Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 26.4. South America Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Neurofibromatosis Type 1 Market

  • 27.1. Brazil Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.2. Brazil Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 27.3. Brazil Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Neurofibromatosis Type 1 Market

  • 28.1. Middle East Neurofibromatosis Type 1 Market Overview
  • 28.2. Middle East Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.3. Middle East Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 28.4. Middle East Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Neurofibromatosis Type 1 Market

  • 29.1. Africa Neurofibromatosis Type 1 Market Overview
  • 29.2. Africa Neurofibromatosis Type 1 Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.3. Africa Neurofibromatosis Type 1 Market, Segmentation By Disease Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
  • 29.4. Africa Neurofibromatosis Type 1 Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Neurofibromatosis Type 1 Market Competitive Landscape And Company Profiles

  • 30.1. Neurofibromatosis Type 1 Market Competitive Landscape
  • 30.2. Neurofibromatosis Type 1 Market Company Profiles
    • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.2. F. Hoffmann-La Roche Ltd Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.3. Merck & Co. Inc Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.4. Novartis AG Overview, Products and Services, Strategy and Financial Analysis
    • 30.2.5. AstraZeneca Plc Overview, Products and Services, Strategy and Financial Analysis

31. Neurofibromatosis Type 1 Market Other Major And Innovative Companies

  • 31.1. Takeda Pharmaceutical Company Limited
  • 31.2. Boehringer Ingelheim International GmbH
  • 31.3. Vertex Pharmaceuticals Incorporated
  • 31.4. Shanghai Fosun Pharmaceutical (Group) Co. Ltd
  • 31.5. BeiGene Ltd.
  • 31.6. BioMarin Pharmaceutical Inc
  • 31.7. Exelixis Inc.
  • 31.8. Blueprint Medicines Corporation
  • 31.9. SpringWorks Therapeutics Inc
  • 31.10. Onclive LLC
  • 31.11. Healx Limited
  • 31.12. Infixion Bioscience Limited
  • 31.13. NFlection Therapeutics Inc
  • 31.14. Pasithea Therapeutics Corporation
  • 31.15. Mulberry Biotherapeutics Inc.

32. Global Neurofibromatosis Type 1 Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Neurofibromatosis Type 1 Market

34. Recent Developments In The Neurofibromatosis Type 1 Market

35. Neurofibromatosis Type 1 Market High Potential Countries, Segments and Strategies

  • 35.1 Neurofibromatosis Type 1 Market In 2029 - Countries Offering Most New Opportunities
  • 35.2 Neurofibromatosis Type 1 Market In 2029 - Segments Offering Most New Opportunities
  • 35.3 Neurofibromatosis Type 1 Market In 2029 - Growth Strategies
    • 35.3.1 Market Trend Based Strategies
    • 35.3.2 Competitor Strategies

36. Appendix

  • 36.1. Abbreviations
  • 36.2. Currencies
  • 36.3. Historic And Forecast Inflation Rates
  • 36.4. Research Inquiries
  • 36.5. The Business Research Company
  • 36.6. Copyright And Disclaimer